{"type":"trials","record":{"id":35103,"source_id":"clinicaltrials-gov","external_id":"NCT07282379","title":"Association Between Geriatric Frailty and Medication Related Problems in the Emergency Department to Help Clinical Pharmacists Prioritise Patients","brief_summary":"The healthcare systems are under increasing pressure due to a rise in emergency consultations, staff shortages, an ageing population and rising costs. Emergency departments are seeing more vulnerable patients, including elderly people, who are often on multiple medications and at risk of medication errors. To improve safety, the integration of pharmacists specialising in emergency medicine has proven beneficial: their presence in the team improves the detection of medication-related problems, speeds up and optimises treatment, reduces rehospitalisations and lowers healthcare costs. However, in most countries, these pharmacists are still rarely found in emergency departments, mainly due to a lack of resources and clinical prioritisation criteria tailored for them and adapted to this environment. Frailty screening tools and scores, such as ISAR, can be used to identify the elderly patients most at risk, predict adverse events such as fall or mortality, and thus adapt their care in the emergency department. Indeed, elderly frail patients often take many medications and consequently are at risk of medication errors, adverse events, inappropriate prescriptions or serious drug interactions. These patients may therefore require a specialised review on their medication by clinical pharmacists when they are admitted to the emergency department, but their high number make it impossible to care for all of them. We aim thus to evaluate the association between frailty (according to the ISAR score) and medication-related problems among elderly patients admitted to the emergency department. Researchers will examine whether this score can predict the presence of inappropriate prescribing and high-risk drug interactions. If so, pharmacists would then have a quick and easy tool to prioritise patients who would benefit most from a specialised review of their medications when they visit the emergency department. There will not be any intervention and this study will not influence patients care. Once patients agree to participate, researchers will prospectively collect medical data from elderly patients admitted to the emergency department and analyse their medical history, home medication, reason for admission, frailty score using ISAR, and perform a pharmaceutical analysis based on these data.","overall_status":"Not Yet Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Pharmacie des Hopitaux de l'Est Lemanique","enrollment":300,"countries":["Switzerland"],"start_date":"2026-03-01","completion_date":"2026-09-01","last_update_date":"2025-12-15","source_url":"https://clinicaltrials.gov/study/NCT07282379","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:20.087268+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":"DISARMED","age_range":"75 Years","comparator":null,"organization":"Pharmacie des Hopitaux de l'Est Lemanique","interventions":["Pharmaceutical analysis based on the Electronic Patient Record"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The rate of inappropriate prescription (PIP) as a function of their ISAR score. — At the time of their admission to the…","The rate of high-risk drug-drug interactions (DDIs) as a function of their ISAR score. — At the time of their admission…","The predictive performance of the ISAR score for the detection of PIPs and high-risk DDIs. — At the time of their admis…"],"design_description":null,"source_has_results":false},"controlled_terms":["Frailty","Emergency Department Visit","Elderly","Drug Drug Interaction","Inappropriate Drug Use","Pharmaceutical analysis based on the Electronic Patient Record"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct07282379","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-03-01 to 2026-09-01","comparator":null,"confidence":"structured-source","population":"ALL · 75 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.475Z","intervention":["Pharmaceutical analysis based on the Electronic Patient Record"],"participants":300,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The rate of inappropriate prescription (PIP) as a function of their ISAR score. — At the time of their admission to the…","The rate of high-risk drug-drug interactions (DDIs) as a function of their ISAR score. — At the time of their admission…","The predictive performance of the ISAR score for the detection of PIPs and high-risk DDIs. — At the time of their admis…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Source terminology contains: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/35103","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}